Results 231 to 240 of about 35,220 (306)

Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders

open access: yesAndrology, Volume 14, Issue 4, Page 1002-1016, May 2026.
Abstract The hypothalamic–pituitary–gonadal axis is regulated by the gonadotropin‐releasing hormone pulse generator in the hypothalamus. This is comprised of neurons that secrete kisspeptin in a pulsatile manner to stimulate the release of GnRH, and, in turn, downstream gonadotropins from the pituitary gland, and subsequently sex steroids and ...
Aureliane C. S. Pierret   +5 more
wiley   +1 more source

The Conjugated Bile Acids Profile Suggests a Novel Liver‐Muscle Axis Associated With Sarcopenia in Chronic Liver Disease

open access: yesLiver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background Liver‐related sarcopenia is a devastating systemic complication of chronic liver disease (CLD) driven by mechanisms extending beyond nutritional deficiency. However, the role of liver‐derived humoral factors remains unclear. We utilised a unique cohort of human skeletal muscle biopsies to test the hypothesis that serum conjugated ...
Motoh Iwasa   +16 more
wiley   +1 more source

Connexin43 Deficiency Leads to Ventricular Arrhythmias by Reprogramming Proline Metabolism

open access: yesAdvanced Science, Volume 13, Issue 19, 2 April 2026.
The study demonstrated that connexin43 (Cx43) knockout caused arrhythmic phenotype and decreased proline content in vitro and in vivo. Mechanistically, Cx43 interacts with the amino acid transporter SNAT2 (sodium‐dependent neutral amino acid transporter), and its deficiency disrupts proline transport and metabolism.
Hangying Ying   +8 more
wiley   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

open access: yesAdvanced NanoBiomed Research, Volume 6, Issue 4, April 2026.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari   +5 more
wiley   +1 more source

Annual Banned‐Substance Review 18th Edition—Analytical Approaches in Human Sports Drug Testing 2024/2025

open access: yesDrug Testing and Analysis, Volume 18, Issue 4, Page 458-482, April 2026.
New insights into drug metabolism, distribution, elimination, and detection assays for drugs and methods of sports doping published between 2024 and 2025 are critically reviewed and evaluated in context with the Prohibited List 2025 as established by the World Anti‐Doping Agency.
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley   +1 more source

Skeletal Muscle and Circulating microRNAs Adaptations to 12‐Week HIIT With or Without L‐Citrulline in Obese Older Adults

open access: yesJournal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 2, April 2026.
ABSTRACT Background High‐intensity interval training (HIIT) with or without L‐citrulline (CIT) oral supplementation improves body composition, functional capacities and muscle health in obese older adults, potentially through microRNA‐driven regulation.
Alexandre Mercier‐Guery   +13 more
wiley   +1 more source

High‐Purity Functional Corneal Endothelial Cells From Human Induced Pluripotent Stem Cells via a Novel Wash‐Out Method

open access: yesMedComm, Volume 7, Issue 4, April 2026.
iPSC‐derived corneal endothelial cells purified via a novel wash‐out method show high functional fidelity, resemble primary CECs, and restore corneal clarity in vivo, offering a scalable alternative to donor transplantation. ABSTRACT Corneal endothelial failure can cause blindness, with transplantation as the only treatment.
Eun‐Ah Ye   +10 more
wiley   +1 more source

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

open access: yesMedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Home - About - Disclaimer - Privacy